Treatment of Metastatic Breast Carcinoma Refactory to Doxorubicin with Liposomal-Annamycin

Abstract

Fourteen patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 25 doses of liposomal- annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50% of patients. No antitumor responses were seen.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 1999
Accession Number
ADA386742

Entities

People

  • Aysegul A. Sahin

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Animals
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Carcinoma
  • Diseases And Disorders
  • Electronic Mail
  • Federal Law
  • Information Operations
  • Laboratory Animals
  • Materials
  • Neoplasms
  • Recombinant Dna
  • Therapy
  • Toxicity

Fields of Study

  • Medicine

Readers

  • Oncology (Cancer Research).